chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pain at the injection site, hurt so bad, hurts less now, when they raise their arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain at the injection site, hurt so bad, hurts less now, when they raise their arm) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     Concomitant products included HYDROCODONE BITARTRATE, PARACETAMOL (NORCO) and IBUPROFEN (ADVIL [IBUPROFEN]) for an unknown indication.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (pain at the injection site, hurt so bad, hurts less now, when they raise their arm). At the time of the report, VACCINATION SITE PAIN (pain at the injection site, hurt so bad, hurts less now, when they raise their arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. .
retested positive; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (retested positive) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Concurrent medical conditions included Drug allergy.   On 08-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (retested positive). At the time of the report, COVID-19 (retested positive) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On an unknown date, SARS-CoV-2 test: negative (Negative) Negative.         No concomitant was reported by patient. Patient completed antiviral for 5 days, tested negative days 5-7. Patient still feeling unwell after 10 days, then progressively worse around what would be day 12 and retested positive.  Patient had taken 3 dose of Moderna vaccine on left arm. It was unknown if patient was taking any other medications or products within 2 weeks of starting COVID-19 treatment, patient previously receive a COVID-19 Vaccine. Patient reported Device Date as 20-May-2022. Treatment medication was not reported by patient.  Company comment- This spontaneous case concerns a 45-year-old male patient with no relevant medical history, who experienced unexpected, non-serious adverse event of special interest Covid-19 which occurred at an unknown time with regards to the mRNA-1273 vaccination. The patient completed the course of antiviral for 5 days and tested negative from days 5 to 7 but he still felt unwell after 10 days. His symptoms became worse on the 12th day, and he retested positive again. The outcome of the events was reported as not resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 45-year-old male patient with no relevant medical history, who experienced unexpected, non-serious adverse event of special interest Covid-19 which occurred at an unknown time with regards to the mRNA-1273 vaccination. The patient completed the course of antiviral for 5 days and tested negative from days 5 to 7 but he still felt unwell after 10 days. His symptoms became worse on the 12th day, and he retested positive again. The outcome of the events was reported as not resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
This spontaneous report was received from a physician assistant and refers to a 24 year old female patient. There was no information about the patient's pertinent medical history and concomitant medication. The patient had an allergy to penicillin. On an unknown date, the patient was vaccinated with the first dose of GARDASIL 0.5 ml, intramuscularly (site of administration, lot # and expiration date were not reported) for Human Papillomavirus (HPV). On an unknown date (1 month after first dose), the patient was vaccinated with the second dose of GARDASIL 0.5 ml, intramuscularly (site of administration, lot # and expiration date were not reported) for HPV. On an unknown date (6 months after first dose), the patient was vaccinated with the third dose of GARDASIL 0.5 ml, intramuscularly (site of administration, lot # and expiration date were not reported) for HPV. On unknown date in September 2015 and on unknown date in 2016, the patient had PAP smear tests with positive result for HPV 16 (it was also reported that there were no adverse events from administered vaccines). The treatment was not given to the event. The outcome of the event was unknown. The causality between the event and the vaccine was not reported. Additional information has been requested.
Blood clot in lower leg.  After ultrasound, Doctor gave treatment protocol.  Still undergoing treatment course.
Immun were given 3JUL91; Woke up Thurs AM w/hives; Started on lt leg above inject site; Had hives on both legs; No fever Seen by MD given DPH & elix & DPH spray;
Information has been received from a pharmacist concerning a male with no drug allergies who on 16-OCT-2007 was vaccinated SC with a dose of ZOSTAVAX (lot number unknown). On 18-OCT-2007 the patient developed erythema at the injection site area. The patient contacted the pharmacist for medical attention. The patient was not recovered. There was no product quality complaint. Follow-up information has been received from a pharmacist indicating on 18-OCT-2007 the patient also developed soreness on the same arm that was vaccinated at an area opposite of the injection (on the posterior side) for ZOSTAVAX (lot# 658084/0888U). Follow-up information has been received from a pharmacist indicating that the 68 year old white male attorney was vaccinated with one SC dose of ZOSTAVAX (lot# 658084/0888U) at 14:00 on 16-OCT-227. Subsequently, the patient recovered from erythema the injection site area and soreness on arm. Additional information has been requested.
This is a spontaneous report received from a non-contactable reporter(s) (consumer or other non-HCP) for a Pfizer sponsored program (159558). A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ANAESTHESIA ORAL (non-serious), outcome "unknown", described as "She stated her friend couldn't feel his tongue for 48 hours". Additional information: Caller spoke to corporate and was threatened with the security department. Pfizer does not care about her privacy or her wait time on calls. The Pfizer covid vaccine was an experiment and that many HCPs are not calling it a vaccine because it's not a vaccine. Covid has a 99% survival rate and its opened millions of people's eyes. We no longer have a government because it's controlled by pharma companies. She stated that back in the 40's pharmacy companies almost went bankrupt because of vaccines. She knows nurses who work in (State name) and that it was all a scare tactic. She stated that children are being forced with vaccines and that people are losing their jobs because they are not taking the vaccine. She stated her friend couldn't feel his tongue for 48 hours. She states that the virus mutates and lives in our DNA. She stated that the Pfizer vaccine was a cocktail and not a vaccine. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient had syncopal episode approx 3 hours after receiving first dose of Moderna Vaccine
patient received the vaccine and within 1 hour felt chills and trembling. she was driving and was worried of losing consciousness so called emergency services when she got home. they advised her to go to the ER. They tried to warm her up with blankets in the ambulance but she was feeling cold the entire time. ER checked her and stated vitals were good, high BP, drew her blood. States her temperature was fluctuating (highest of aroubnd 101/8)- flu like symptoms and flashes
maternal exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a health care professional and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (maternal exposure during pregnancy) in a 33-year-old female patient (gravida 3) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 19-Aug-2020 and the estimated date of delivery was 17-Jun-2021. On 07-Apr-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (maternal exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirty-third week of the pregnancy.  At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (maternal exposure during pregnancy) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient reported  that she is not under medications.
Fever, chills, fatigue. Occurred at noon 12-19-2020. Sent home from work ( ER RN) and had covid test.. awaiting results.
Acute sharp pain in the left shoulder joint.  Pain is worst when lifting to the outside while applying pressure to the arm (think of a lateral dumbbell raise).  Started a couple days after injection and pain has steadily increased each day since.
The patient has a swollen face, bumps all over the body, Temperature of 99., and angioneurotic edema of hands and feet. This started in less than 24 hours and lasted 4 days with continuous improvement.  Prescribed: Decadron, and Benadryl.
light headaches; This is a spontaneous report from a contactable consumer or other non-Health Professional (patient). A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 2 via an unspecified route of administration on 02Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date in Mar2021 the patient experienced light headaches. Patient was asking if it's okay to take Tylenol to relieve the pain (she did not took any medications yet). The outcome of event was unknown.  Information on the lot/batch number is requested.
The case report was received from a (n) Health Professional and concerns a (n) 50 year old female patient. Linked Case ID (s): US-BEH-2016058697 (Same patient). Suspect drug (s), timing and conditions surrounding the onset of reaction (s)/event (s): The patient received an Influenza (seasonal) vaccine for indication not reported in Sep-2015, Batch no: not provided, Route of administration: Unknown, Dose: Unknown. Additional suspect drug (s): No additional drugs suspected. Reaction (s)/event (s) and outcome: On an unknown date, after starting/ treatment with Influenza (seasonal) vaccine the patient experienced an Adverse event (non serious, outcome: Unknown). Reporter's assessment: Not reported. Company's evaluation and comment: Seriousness criterion/criteria: Non serious. Listedness: According to the Reference Safety Information, the event Adverse event is a unlisted event of Influenza (seasonal) vaccine. Case Causality: Unassessable/unclassifiable due to insufficient information.
Low-grade fever, chills, ache all over, cold, swollen arm at site and quite red.
No adverse symptoms reported; the 22 year old patient was vaccinated with a first dose of PROQUAD; This spontaneous report was received from a nurse, regarding a 22-year-old patient of an unknown gender. The patient's medical history, concurrent conditions, concomitant medications and drug reactions/allergies were not reported. On 15-JAN-2020, the patient was vaccinated with the first dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (strength, dose, route, lot # and expiration date were not reported) for prophylaxis (product administered to patient of inappropriate age). No adverse symptoms (no adverse event) were reported. No product quality complaint was reported.
Back pain; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Back pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Injury (She Injured to her lower back.).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BACK PAIN (Back pain). At the time of the report, BACK PAIN (Back pain) outcome was unknown. Not applicable      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment medication was not provided.  The patient had a injury in her lower back before  taking the first dose. She received her first dose and had not taken any pain medication since because she did not think she was allowed to. The patient's back was in a lot of pain from the prior injury and wants to know whether she can take OTC pain medication or not.
Having severe flu like symptoms; Had chest pain; This spontaneous case was reported by a patient family member or friend and describes the occurrence of INFLUENZA LIKE ILLNESS (Having severe flu like symptoms) and CHEST PAIN (Had chest pain) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Having severe flu like symptoms) and CHEST PAIN (Had chest pain). At the time of the report, INFLUENZA LIKE ILLNESS (Having severe flu like symptoms) and CHEST PAIN (Had chest pain) outcome was unknown.            No concomitant medication were reported.  No treatment medication were reported.
chills that then got more severe; watery eyes; sneezing; runny nose; no appetite; fever; body aches; headaches; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (runny nose), LACRIMATION INCREASED (watery eyes), SNEEZING (sneezing), DECREASED APPETITE (no appetite) and CHILLS (chills that then got more severe) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (Medical history not reported ).    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, the patient experienced DECREASED APPETITE (no appetite), PYREXIA (fever), MYALGIA (body aches) and HEADACHE (headaches). On 08-Apr-2021 at 4:00 PM, the patient experienced RHINORRHOEA (runny nose), LACRIMATION INCREASED (watery eyes) and SNEEZING (sneezing). On 08-Apr-2021 at 6:00 PM, the patient experienced CHILLS (chills that then got more severe). On 10-Apr-2021, RHINORRHOEA (runny nose), LACRIMATION INCREASED (watery eyes), SNEEZING (sneezing), DECREASED APPETITE (no appetite), CHILLS (chills that then got more severe), PYREXIA (fever) and MYALGIA (body aches) had resolved. At the time of the report, HEADACHE (headaches) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       For mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular), the reporter did not provide any causality assessments.  Concomitant product use was not provided by the reporter.  No treatment information was reported.
I had been on a trip, returned on June 27, 2022, tested on June 28, 2022. I started feeling congested and thought I had bronchitis but decided to retest on July 2, 2022 this time the home COVID-19 test came back positive. I emailed my doctor who prescribed PAXLOVID so that I could start it the next day. I am pretty much back to normal, low on energy and small productive cough.
Follow Up of Chest pain (chief complaint). Description: The patient presents with a complaint of Follow Up of Chest pain. The symptoms began 2 weeks ago. The problem occurs intermittently. It generally lasts a variable amount of time. The symptoms have improved. The pain is in the substernal area. The patient describes the pain as pressure, stinging, jolting. It radiates to the left arm. Relevant history for this patient excludes tobacco use. Interventions the patient has tried have not provided any relief. The Follow Up of Chest pain is associated with dyspnea on exertion, headache, nocturnal dyspnea and tachycardia. The patient denies any dependent edema, dysphagia, generalized weakness or nocturia. Additional information: Of note chest pain started after first Covid vaccine 1/21 and got second 2/11 and worsened. States is slightly improved since start but is still present. Has been anxious throughout college but has never felt this before.
Patient received second dose of moderna on 6.25.21 at 11:00 a.m. at. The vial the dose was taken from was opened at 9 a.m. on 6/24/21.
Within 5 hours post vax, the pt experienced an achy shoulder and one day later he had a headache and a foggy feeling.
Headache & Palpitations Narrative:  Surgeon reports on 8/2/2021 she has been experiencing the following  symptoms since 7/24/2021: Chest heaviness, palpitations, burping, ankle swelling, headache. Seen by her cardiologist at clinic 7 days ago. Normal Echocardiogram with EF 65%, EKG nsr, BNP 300 (her baseline level.) Reports has h/o X3 mitral valve repair, and x 3 ablation for atrial fibrillation. She  was advised to seek ER care by cardiologist and by employee health on 8/2/21 for troponins, ECG, but declined. Recommended to follow up ASAP in employee health to complete on the job injury claim for vaccine reaction. Employee is off duty today, but states feels well enough to return to duty in clinic on 8/3/21
Initial unsolicited report received from a pharmacist on 26 Oct 2016. This case involves a 12-year-old male patient who was vaccinated with second dose of FLUZONE QIV (batch number: UI678AE, expiry date: 30 Jun 2017, dose, route of administration were not reported) in left deltoid on 25 Oct 2016 at 5:30 PM. Illness at the time of vaccination was reported as none and pre-existing physician diagnosed allergies, birth defects, medical conditions no known allergy (NKA), History of syncope in the past. The patient did not receive any concomitant medications. On 25 Oct 2016 at 5:30 PM, immediately following the vaccination, the patient fainted in the chair they laid him flat on a surface after about 8 seconds during this time he was having decerabrate posturing. Same day the patient held in the clinic for about 30 minutes after the incident and then sent him home with his family." The laboratory investigations were not performed. The corrective treatment was not reported. On 25 Oct 2016, the patient was recovered from the event (decerabrate posturing lasted only a few seconds and he returned to consciousness after 1 min). Upon medical review, the case was considered as serious due to important medical event: having decerabrate posturing. List of documents held by sender: none. Sender's Comments: This case concerns a 12 year old male patient who fainted followed by having a decerebrate posture immediately after receiving INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. Time to onset is compatible with role of vaccine. The subject has a history of syncope in the past. However details such as, previous immunization history and tolerance, concurrent conditions, patient immune status at the time of vaccination and diagnostic work-up to confirm alternative etiology/diagnosis etc. are needed for complete assessment of the case.
The patient went unconscious and was having slight involuntary muscle jerks while on dialysis. The patients blood pressure dropped to 63 systolic. Shortly after a 500ml saline bolus, patient stabilized. Patient left on ambulance by request. This is not believed to be an allergic reaction to the vaccine, but due to the timing, is being reported as an adverse event for review.
This spontaneous report was received from a healthcare professional who reported that in January 2014, 21 improperly stored doses of ROTATEQ, (oral, dose, batch and lot number not reported) were administered by a clinic to an unspecified number of patients (age and gender were not reported). No adverse effects were reported. This is one of several reports from the same source. Follow up information has been received on 17-MAR-2014. All telephone attempts to obtain follow-up information hade been unsuccessful. Follow up information has been received on 23-SEP-2014. Demographic details for each patient were provided. This report referred to a 4-months old female patient, with no know drug allergies and no illness at time of vaccination. The patient was vaccinated with the first dose of ROTATEQ (oral, batch/lot # J004875, expiration date 17-OCT-2014), on 31-JAN-2014 at 11:00 AM. It was reported that this dose was spoiled since the refrigerator was too cold (onset of event also reported as 27-FEB-2014 at 10:00 AM). The patient did not repeat the vaccine. No adverse event was reported for the patient. This is one of several reports from the same source. Additional information is not expected since all follow ups requested to complete the case were received.
PHN symptoms have "gotten worse."; PHN symptoms have "gotten worse."; This case was reported by a consumer via call center representative and described the occurrence of post herpetic neuralgia in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles and post herpetic neuralgia.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 1 month after receiving Shingrix, the patient experienced post herpetic neuralgia and condition aggravated. On an unknown date, the outcome of the post herpetic neuralgia and condition aggravated were not recovered/not resolved.   It was unknown if the reporter considered the post herpetic neuralgia and condition aggravated to be related to Shingrix.  Additional details were reported as follows: Thew age at vaccination was not reported. The patient had a medical history of shingles and post herpetic neuralgia (PHN). The patient stated that 2 to 3 months before reporting received 1st dose of Shingrix. The stated that 1 month ago her Post Herpetic Neuralgia symptoms had gotten worse. The reporter did not consent to follow up. The reporter did not had any other information for this adverse event.
Pt experienced nausea, emesis, rash within 2-3 hrs of injection. No fever or chills - tx'ed with OTC BENADRYL. Symptoms continued. Rx'ed with ZOFRAN.